Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
FASEB J. 2024 Oct 15;38(19):e70089. doi: 10.1096/fj.202401734R.
Cervical, endometrial, and ovarian cancers stand prominently as the leading gynecological malignancies of the female reproductive system. The conventional therapeutic modalities for gynecological malignancies have predominantly encompassed surgery, chemotherapy, and radiotherapy. However, efficacy of these approaches remains limited in cases of relapse or drug resistance. KRAS is one of the most frequently mutated oncogenes in human cancers. The KRAS gene encodes a small guanosine triphosphatase protein that acts as a molecular switch for crucial intracellular signaling pathways. KRAS mutations are deeply involved in the occurrence and development of gynecological malignancies. The present review aims to expound upon the role of oncogenic KRAS as a biomarker, elucidating various therapeutic approaches under investigation targeting the KRAS pathway in gynecological tumors.
宫颈癌、子宫内膜癌和卵巢癌是女性生殖系统中主要的妇科恶性肿瘤。妇科恶性肿瘤的传统治疗方法主要包括手术、化疗和放疗。然而，在复发或耐药的情况下，这些方法的疗效仍然有限。KRAS 是人类癌症中最常突变的癌基因之一。KRAS 基因编码一种小分子鸟苷三磷酸酶蛋白，作为关键细胞内信号通路的分子开关。KRAS 突变深度参与妇科恶性肿瘤的发生和发展。本综述旨在阐述致癌 KRAS 作为生物标志物的作用，并阐明针对妇科肿瘤中 KRAS 通路的各种研究中的治疗方法。
